[{"id":"9ae59dca-ede6-4775-8369-db749ef71325","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409343","created_at":"2021-01-18T05:47:52.029Z","updated_at":"2024-07-02T16:36:30.589Z","phase":"Phase 1","brief_title":"TrasGEX™: Phase 1 Study in Cancer Patients","source_id_and_acronym":"NCT01409343","lead_sponsor":"Glycotope GmbH","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TrasGEX (timigutuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2021-05-07"}]